MYNZ Share Price Performance
US$1.50
-8.30 (-84.69%)
Price US$1.50
Share PriceUS$1.50
Mainz Biomed N.V. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 8 Fair Values set on narratives written by author
MYNZ Community Narratives
There are no narratives available yet.
There are no community narratives available.
Snowflake Analysis
Mainz Biomed N.V. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- -3.50
- 67.50%
- -2,874.69%
- 64.3%
About MYNZ
- Founded
- 2008
- Employees
- 23
- CEO
- WebsiteView website
Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe. It offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. The company also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. In addition, it operates a clinical diagnostic laboratory; and distributes its IVD kits to third-party laboratories. The company has a collaboration agreement with Thermo Fisher Scientific Inc. for the development and commercialization of colorectal cancer screening product. Mainz Biomed N.V. was founded in 2008 and is based in Mainz, Germany.
